Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133626 | 0.93 | HDAC1 (0.45) | HDAC1ADORA2AADORA1HDAC3KCNH2 | |
| SCHEMBL6133384 | 0.90 | ADORA2A (0.50) | ADORA2AADORA1ADORA3KDM4EMEN1 | |
| SCHEMBL6133303 | 0.89 | ADORA2A (0.60) | ADORA2AADORA1ADORA3MEN1MAPT | |
| SCHEMBL6133433 | 0.88 | ADORA2A (0.48) | ADORA2AADORA1ADORA3KDM4EMEN1 | |
| SCHEMBL6133582 | 0.88 | ADORA2A (0.43) | HDAC1ADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL6133349 | 0.87 | ADORA2A (0.53) | ADORA2AADORA1ADORA3MEN1MAPT | |
| SCHEMBL6134298 | 0.87 | ADORA2A (0.53) | ADORA2AADORA1ADORA3KDM4EMAPT | |
| SCHEMBL6133257 | 0.87 | SMN1; SMN2 (0.56) | ADORA2AADORA1ADORA3KDM4EMEN1 | |
| SCHEMBL6133270 | 0.86 | ADORA2A (0.49) | HDAC1ADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL6133770 | 0.86 | ADORA2A (0.46) | ADORA2AADORA1ADORA3KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004134-A1 | Thiazole derivative and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1441732-A2 | THIAZOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003039451-A2 | THIAZOLE PYRIDAZINONES AS ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004134-A1 | Thiazole derivative and pharmaceutical use thereof | MC2R, CYP2C9, OXTR | HDAC1 601/4885ADORA2A 635/4885ADORA1 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.